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Abstract
Background: We have previously reported activating mutations of the gene coding for the
fibroblast growth factor receptor 3 (FGFR3) in invasive cervical carcinoma. To further analyze the
role of FGFR3 in cervical tumor progression, we extended our study to screen a total of 75 invasive
tumors and 80 cervical intraepithelial neoplasias (40 low-grade and 40 high-grade lesions).
Results: Using single strand conformation polymorphism (SSCP) followed by DNA sequencing, we
found FGFR3 mutation (S249C in all cases) in 5% of invasive cervical carcinomas and no mutation
in intraepithelial lesions. These results suggest that, unlike in bladder carcinoma, FGFR3 mutation
does not or rarely occur in non invasive lesions. Compared to patients with wildtype FGFR3 tumor,
patients with S249C FGFR3 mutated tumors were older (mean age 64 vs. 49.4 years, P = 0.02), and
were more likely to be associated with a non-16/18 HPV type in their tumor. Gene expression
analysis demonstrated that FGFR3 mutated tumors were associated with higher FGFR3b mRNA
expression levels compared to wildtype FGFR3 tumors. Supervised analysis of Affymetrix
expression data identified a significant number of genes specifically differentially expressed in
tumors with respect to FGFR3 mutation status.
Conclusion: This study suggest that tumors with FGFR3 mutation appear to have distinctive
clinical and biological characteristics that may help in defining a population of patients for FGFR3
mutation screening.
Background
Cervical cancer is the second leading cancer in women
worldwide and a common cause of death among women
in developing countries where 80% of cases occur [1].
Invasive cervical carcinoma develops through a well-
defined progression model. Cervical intraepithelial neo-
plasia (CIN) is the premalignant lesion that always pre-
cedes invasive squamous cell carcinoma [2]. These
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precursor lesions are subdivided into 3 grades (CIN I-III)
or 2 grades (low-grade squamous intraepithelial lesions,
LSIL and high-grade squamous intra-epithelial lesions,
HSIL). Half of low-grade lesions spontaneously regress
within 6 months although 10–20% of high-grade lesions
may progress to invasive carcinomas [3]. Molecular epide-
miologic studies clearly demonstrated that sexually trans-
mitted infection by HPV (human papillomavirus) is the
principal cause of cervical carcinoma. Fifteen HPV types
are considered as high-risk HPV and are associated with a
higher risk of developing invasive cervical carcinoma from
squamous intraepithelial lesions [4]. However, HPV
infection is not sufficient to transform the normal cervix
epithelial cells to invasive carcinomas and several addi-
tional events are necessary. Only a few genetic alterations
have been reported in cervical carcinoma so far.
We previously reported specific FGFR3 missense muta-
tions in 3 out of 12 invasive cervical carcinomas [5].
FGFR3 belongs to a family of structurally related tyrosine
kinase receptors encoded by four different genes (FGFR1-
4). FGFRs are glycoproteins composed of two or three
extracellular immunoglobulin (Ig)-like domains, an
hydrophobic transmembrane region and a cytoplasmic
part that contains the tyrosine catalytic site. FGFRs are
present as inactive monomers on the cell surface, upon
ligand binding FGFRs dimerize, autophosphorylate and
are able to transmit a series of intracellular signals [6]. An
alternative splicing event in the second half of the juxtam-
embrane Ig-like domain of FGFR3 generates two mutually
exclusive isoforms : FGFR3b the main form expressed in
epithelial cells and FGFR3c the main form expressed in
chondrocytes. Germinal activating FGFR3 mutations
result in craniosynostoses and dwarfing chondrodyspla-
sias of varying severity (hypochondroplasia, achondropla-
sia, SADDAN and thanatophoric dysplasia). Strikingly the
same activating mutations have been reported at the
somatic level in several types of cancer: multiple mye-
loma, bladder and cervical carcinomas. Very frequent in
bladder carcinoma, particularly in non invasive papillary
tumours (pTa tumors) (70% of cases harbor mutations),
FGFR3 mutations are more rare in multiple myeloma and
cervical carcinomas [5,7,8].
The goal of this work is to extend our previous study to
screen a total of 75 patients for FGFR3 mutations and to
identify clinical and/or pathological features associated
with FGFR3 mutation. We also asked whether FGFR3
mutation could occur at earlier stages of cervical tumor
progression, like in bladder tumors for which the highest
rate of mutation is for low-stage non invasive pTa tumors.
We thus analyzed 80 squamous intra-epithelial lesions
(40 LSILs and 40 HSILs).
Results
FGFR3 mutation in invasive cervical carcinoma and 
squamous intraepithelial lesions
To extend our previous report of FGFR3 mutation in 3 of
12 cervical carcinomas [5], we selected 63 additional cases
for a total of 75 screened DNAs. Those patients had the
same characteristics than the initial cohort of 12 patients.
SSCP analysis was performed on exons 7, 10, 15, and 20
of FGFR3, followed by direct DNA sequencing for cases
with abnormal SSCP profiles. We found one additional
case with FGFR3 mutation. Taken together, our study
showed FGFR3 mutation in 4 of 75 invasive cervical can-
cer (5%) (Table 1). All mutations were C to G transversion
at nucleotide 746, which changed serine 249 to cysteine.
This S249C mutation creates a cysteine residue in the
extracellular domain of the FGFR3 receptor.
To further analyze the role of FGFR3 in cervical tumor
progression, we investigated whether FGFR3 mutations
are restricted to invasive carcinoma or may occur in squa-
mous intraepithelial lesions. Hence we analyzed DNA
from 40 LSILs and 40 HSILs. SSCP revealed no FGFR3
mutation in any of these cases. For all SSCP experiments,
positive controls carrying all somatic FGFR3 mutations
previously identified in tumors have been included. The
rate of FGFR3 mutation in invasive cervical carcinoma is
significantly different from the one in squamous intraep-
ithelial lesions (P = 0.036, chi-square test).
Overall FGFR3 mutation rate in invasive cervical 
carcinoma
Studies about FGFR3 mutation in cervical cancer reported
various rates of mutation, ranging from 0% to 25%. In
Table 1: FGFR3 mutations in 75 invasive cervical carcinoma samples
Sample Age Stage Histology HPV Codon Mutation Predicted effect
6.96.1 65 IB SCC + * 249 TCC →  TGC Ser →  Cys
4.139 69 IIB SCC 33 249 TCC →  TGC Ser →  Cys
4.13 64 IIB SCC 16 249 TCC →  TGC Ser →  Cys
7.79.1 58 IIB SCC + * 249 TCC →  TGC Ser →  Cys
* Tumors with HPV DNA sequences of undetermined type (other than HPV 6, 11, 16, 18, 31, 33, 35, 39, 42, 45, 52 and 58). SCC : Squamous Cell 
CarcinomaMolecular Cancer 2005, 4:15 http://www.molecular-cancer.com/content/4/1/15
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order to evaluate an overall mutation rate, we added all
results. Hence, we searched for all published papers on
FGFR3 mutations in cervical cancer, by interrogating
Medline with the terms "cervical cancer" and "FGFR3"
(Table 2). Including this work, 6 studies analyzed a total
of 349 cervical cancer samples and found 6 FGFR3 muta-
tions (1.7%) [5,9-12]. All mutations were S249C mis-
sense mutations.
Patients with FGFR3 mutation are older that patients with 
wild-type FGFR3
Clinical and pathological features were retrieved from
patient's charts and correlated with FGFR3 status (Table
1). The 4 patients with S249C FGFR3 mutation tumor
were significantly older at time of diagnosis than patients
without the S249C FGFR3 mutation in the tumor (mean
age 64 vs. 49.4 years, P = 0.02, Mann-Whitney U test).
Clinical stage was IIB for 3 patients and IB for 1 patient.
One patient died from the disease after 19 months. Fol-
low-up information for the other 3 patients was available
only for 3 months, 47 months, and 81 months, with no
sign of relapse.
All 4 mutated tumors were well-differentiated invasive
squamous cell carcinomas. HPV DNA of various types was
detected in all cases : one HPV16, one HPV33 and two
HPV of undetermined type (other than HPV 6, 11, 16, 18,
31, 33, 35, 39, 42, 45, 52 and 58). Distribution of HPV
types associated with FGFR3 mutated tumors was rather
different than the expected distribution in squamous cell
cervical carcinoma. The prevalence of HPV16, HPV33 and
HPV of another type of those determined by our PCR
method in squamous cell carcinoma is approximately
55%, 2%, and less than 10%, respectively [4,13]. Thus,
the probability to have 2 tumors with HPV of undeter-
mined type in our series would be less than 1%.
FGFR3 mRNA expression is higher in tumors with S249C 
FGFR3 mutation
S249C FGFR3 mutation has been initially described in
constitutional DNA from individuals with thanatophoric
dysplasia [14]. It is suggested that activation of FGFR3
results from formation of intermolecular disulfide bonds
between 2 mutant FGFR3 monomers. In order to get
insight about association between S249C FGFR3 muta-
tion and expression, we analyzed FGFR3b expression by
semi-quantitative PCR in normal cervical samples and in
invasive carcinomas (Figures 1, 2 and data not shown). In
17 normal cervix samples, FGFR3b/TBP mRNA ratios was
4.16 ± 0.72 in exocervical specimens and 0.35 ± 0.17 in
endocervical specimens (Figure 1). Difference in of
FGFR3b/TBP mRNA ratio means in exocervix and
endocervix was statistically significant (P < 0.001, Mann-
Table 2: Total number of cervical carcinoma cases screened for FGFR3 mutation, as of august 2004.
Study Method Total number 
of cases
Mutated cases 
(percentage)
Cappellen et al. [5] SSCP (entire coding region) 12 3 (25%)
Yee et al. [9] Direct sequencing (exon 7) 104 0
Wu et al. [10] Direct sequencing (exons 7, 10, 13, 15, and 19) 51 1 (2%)
Dai et al. [11] Amplification created restriction site methodology for S249C mutation 91 0
Sibley et al. [12] Direct sequencing (exons 7, 10, and 15) 28 1 (3.5%)
Present study SSCP (exons 7, 10, and 15) 63 1 (1.5%)
Total 349 6 (1.7%)
Schematic results of FGFR3b expression level in normal  exocervix (n = 10) and normal endocervix (n = 7) Figure 1
Schematic results of FGFR3b expression level in normal 
exocervix (n = 10) and normal endocervix (n = 7). FGFR3b 
expression is significantly higher in exocervix compared to 
endocervix.Molecular Cancer 2005, 4:15 http://www.molecular-cancer.com/content/4/1/15
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Whitney U test). FGFR3b mRNA levels was determined in
62 cervical carcinoma cases, including the 4 S249C
mutated cases. Tumors with S249C mutation showed a
significantly higher FGFR3b/TBP mRNA ratio than
tumors without the S249C mutation (30.92 ± 21.74 vs.
2.27 ± 0.36, P = 0.002, Mann-Whitney U test) (Figure 2).
We then sought for a correlation between survival and
FGFR3b expression level. When patients were subdivided
into 2 or 3 groups of equal size according to FGFR3b/TBP
levels in cervical carcinoma, there was no statistically sig-
nificant difference in survival between these groups. How-
ever, when patients were subdivided into 3 groups, there
was a trend for patients with low levels of FGFR3b/TBP to
have a shorter survival compared to the 2 other groups of
patients with higher levels of FGFR3b/TBP (P = 0.12, Log-
rank test) (Figure 3).
Differentially expressed genes in FGFR3 mutated tumors 
compared to FGFR3 wildtype tumors
Finally, we used gene expression data from Affymetrix oli-
gonucleotide microarray hybridization of invasive cervi-
cal carcinomas [15]. As all tumors with FGFR3 mutations
were of the squamous type, we only used gene expression
profiles from squamous cell carcinomas to compare
tumors of same histological type and to minimize gene
expression differences caused by different histology. We
compared expression profiles of 3 FGFR3 mutated cervical
carcinomas with the expression profiles of 17 wildtype
FGFR3 cervical carcinomas, using SAM analysis as
described in the methods section. With a threefold differ-
ential cutoff, we found 262 probe sets expressed at higher
level and 552 probe sets at lower levels in FGFR3 mutated
tumors compared to wildtype FGFR3 tumors (see addi-
tional files 1 and 2). To restrict the number of genes, we
FGFR3b mRNA expression in normal cervix and invasive cervical carcinoma, using semi-quantitative RT-PCR with TBP as ref- erence gene Figure 2
FGFR3b mRNA expression in normal cervix and invasive cervical carcinoma, using semi-quantitative RT-PCR with TBP as ref-
erence gene. The level of FGFR3b mRNA expression was measured in 3 normal exocervix epithelia, 2 underlying connective 
tissues (C.T.), 4 invasive cervical carcinomas with S249C FGFR3 mutation (*) and 14 invasive cervical carcinomas with wildtype 
FGFR3.
Survival stratified for the FGFR3b/TBP levels of invasive cer- vical carcinoma Figure 3
Survival stratified for the FGFR3b/TBP levels of invasive cer-
vical carcinoma. Kaplan-Meier survival curves compare the 
cumulative probability of survival after diagnosis among 
patients with low FGFR3b/TBP levels to those with high 
FGFR3b/TBP levels.Molecular Cancer 2005, 4:15 http://www.molecular-cancer.com/content/4/1/15
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arbitrarily set a cutoff q value at 0.20 for higher expressed
probe sets to end up with 61 probe sets, corresponding to
51 different known genes (Table 3). Genes with a role in
regulation of transcription were the most frequently rep-
resented, including POU6F2, NHLH2, NR1D1, and ST18.
Table 3: Genes with higher expression in FGFR3 mutated cervical carcinomas compared to wildtype FGFR3 cervical carcinomas.
Gene Symbol Gene Title
ABCB9 ATP-binding cassette, sub-family B (MDR/TAP), member 9
ACACA acetyl-Coenzyme A carboxylase alpha
ANKRD6 ankyrin repeat domain 6
APIN APin protein
AVP arginine vasopressin
C8A complement component 8, alpha polypeptide
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta 3 subunit
CACNB2 calcium channel, voltage-dependent, beta 2 subunit
CALML3 calmodulin-like 3
CAMK1G calcium/calmodulin-dependent protein kinase IG
CAMK2B calcium/calmodulin-dependent protein kinase II beta
CCL13 chemokine (C-C motif) ligand 13
CPEB1 cytoplasmic polyadenylation element binding protein 1
DBP D site of albumin promoter (albumin D-box) binding protein
DDO D-aspartate oxidase
ED1 ectodermal dysplasia 1, anhidrotic
FBXO26 F-box only protein 26
FGFR3 fibroblast growth factor receptor 3
FTHFD formyltetrahydrofolate dehydrogenase
GNAO1 guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O
GRIK4 glutamate receptor, ionotropic, kainate 4
GUCA2B guanylate cyclase activator 2B
HIG2 hypoxia-inducible protein 2
KCNE1L potassium voltage-gated channel, Isk-related family, member 1-like
LPHN3 latrophilin 3
MDM2 Mdm2, transformed 3T3 cell double minute 2
MEP1A meprin A, alpha (PABA peptide hydrolase)
MYF6 myogenic factor 6 (herculin)
NEFH neurofilament, heavy polypeptide 200kDa
NHLH2 nescient helix loop helix 2
NR1D1 nuclear receptor subfamily 1, group D, member 1
NRN1 neuritin 1
OGDHL oxoglutarate dehydrogenase-like
POU6F2 POU domain, class 6, transcription factor 2
PPFIA4 protein tyrosine phosphatase, receptor type, f polypeptide
PVRL1 poliovirus receptor-related 1
RAPGEF3 Rap guanine nucleotide exchange factor (GEF) 3
RHAG Rhesus blood group-associated glycoprotein
RNF6 ring finger protein (C3H2C3 type) 6
SLC4A3 solute carrier family 4, anion exchanger, member 3
SLC6A15 solute carrier family 6 (neurotransmitter transporter), member 15
SLC6A8 solute carrier family 6 (neurotransmitter transporter, creatine), member 8
SLC7A8 solute carrier family 7 (cationic amino acid transporter, y+ system), member 8
SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
ST18 suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein)
TFAP2B transcription factor AP-2 beta
TRIM2 tripartite motif-containing 2
UPB1 ureidopropionase, beta
ZNF257 zinc finger protein 257
ZNF287 zinc finger protein 287
ZXDA zinc finger, X-linked, duplicated AMolecular Cancer 2005, 4:15 http://www.molecular-cancer.com/content/4/1/15
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FGFR3 was among the differentially expressed genes and
was found upregulated, in agreement with RT-PCR results.
Discussion
Since its first description, the role of FGFR3 mutation in
cervical carcinoma has been debated when some studies
reported an absence of mutation in a total of nearly 200
cases analyzed [9,11]. Here we showed that FGFR3 is
mutated in 5% (4 of 75 cases) of invasive cervical carcino-
mas from a French cohort of patients (including 3 cases
previously reported [5]). When all study results are
grouped, the overall FGFR3 mutation rate in cervical car-
cinoma worldwide is 1.7%.
In bladder neoplasias, FGFR3 mutation characterizes low-
grade low-stage pTa bladder tumors and is rarely found in
advanced stage bladder carcinoma [16,17]. The low rate of
FGFR3 mutation in invasive cervical carcinoma could
result from the same distribution pattern, FGFR3 muta-
tion being found at higher frequency in intraepithelial
non invasive lesions. Here, we show that no mutation was
identified in 80 cervical squamous intraepithelial lesions.
To better characterize FGFR3 mutated cervical tumors and
to find explanations for the apparent discrepancy in muta-
tion rates, we looked for clinical and pathological features
that may be specifically associated with FGFR3 mutation.
We showed that FGFR3 mutated tumors are more likely to
be associated with a non-HPV16/18 type and that patients
with mutated FGFR3 cervical carcinoma are older than
patients with wildtype FGFR3 tumor. Epidemiologic stud-
ies have found an increase in prevalence with age for
minor HPV types, such as types 39, 52, and 58 [4]. Age
and association with minor HPV types may thus not be
independent characteristics of patients with FGFR3
mutated cervical tumor. We can hypothesize that varia-
tions in reported FGFR3 mutation rate are, at least in part,
related to differences in HPV types and in age distribution
of studied patients. We cannot exclude that variations in
FGFR3 mutation rate could also be related to other param-
eters, such as ethnic differences.
To get more insight into the biological significance of dif-
ference in FGFR3 mutated tumors, we sought for gene
expression of FGFR3 in cervical tissues. FGFR3b expres-
sion is significantly higher in normal exocervix compared
to normal endocervix and in FGFR3 mutated tumors com-
pared to FGFR3 wildtype tumors. It has been suggested
that the substitution of serine to cysteine in codon 249
may result in formation of intermolecular disulfide bond
in the extracellular domain of two mutants FGFR3, caus-
ing a constitutive activation of the receptor [14]. It has
been reported that activated FGFR3 results in activation of
Jak/STAT pathway with STAT1 and STAT5 phsphorylation
[18,19]. Here, we show for the first time that activation of
FGFR3 is associated with an increase in FGFR3b expres-
sion in S249C mutated tumors. In bladder carcinoma, we
also found a significantly higher FGFR3b expression in
mutated tumors compared to wildtype tumors (unpub-
lished data). Supervised analysis of Affymetrix expression
data using SAM algorithm identified a significant number
of genes that are up- or down-regulated in FGFR3 mutated
tumors. These genes are potential targets of activated
FGFR3. The small number of tumors in one group (3 vs.
17) may account for a high 0.20 false discovery rate for
genes at higher expression in FGFR3 mutated tumors.
However, the presence of FGFR3 in this list provides some
evidence for the significance of these genes.
Finally, we found that patients with low FGFR3b expres-
sion in tumors are more likely to have a shorter survival
than patients with high FGFR3b levels. Dai et al reported
similar findings in an immunohistochemical study of 73
cervical carcinomas [11]. They found that patients with
intense FGFR3 immunolabeling in tumor cells had a bet-
ter prognosis. These results, not statistically significant in
both studies, require further investigations.
Conclusion
In summary, we demonstrated that S249C FGFR3 muta-
tion defines a small subset of invasive cervical carcinoma
and is not found in precursor intraepithelial lesions.
Albeit small in number, patients with FGFR3 mutation
appear to have distinctive clinical and biological charac-
teristics that may help in defining a population for FGFR3
mutation screening. Gene expression analysis suggests
that FGFR3 mutated tumors have a different biology with
higher FGFR3b expression and differentially expressed
genes which are potential targets of activated FGFR3.
Methods
Tissue specimens
Seventeen normal cervical mucosa and 75 invasive cervi-
cal carcinoma samples were obtained from the Institut
Curie Hospital. The normal cervical mucosa samples were
collected by scraping the cervix surface with a razor blade
from 13 surgical resection specimens (hysterectomy or
conization). Localization of normal samples was the
exocervix (n = 10) and the endocervix (n = 7). Cervical car-
cinoma samples were collected from 75 patients with a
median age of 48 years (range 23–82 years). Twelve of
these samples had been previously studied for FGFR3
mutation [5]. Clinical stages according to the Interna-
tional Federation of Gynecology Obstetrics (FIGO) stag-
ing system were IB for 38 patients, IIA for 6 patients, IIB
for 21 patients, IIIA for 3 patients, and IIIB for 6 patients.
No staging information was available for 1 patient.
Median follow-up was 32 months. In 73 cases, carcinoma
samples originated from the initial cervical biopsy before
any treatment, except in one case in which the patient pre-Molecular Cancer 2005, 4:15 http://www.molecular-cancer.com/content/4/1/15
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viously received radiotherapy treatment. In 2 cases, the
tumor sample was a pelvic recurrence after treatment.
Final histological diagnoses were invasive squamous cell
carcinoma (n = 66) and invasive adenocarcinoma (n = 9).
HPV status was determined as previously described [20].
Briefly, Southern blot hybridization was the first-step pro-
cedure, using specific probes for HPV 6, 11, 16, 18, 31, 33,
35, 39, 42, 45, 52 and 58. A PCR with consensus primers
in the L1 open reading frame was performed on cases neg-
ative by Southern blot hybridization. HPV DNA
sequences were detected in 66/75 specimens (88%): 43
HPV16, 12 HPV18, 2 HPV33, 1 HPV31, 1 HPV58, and 7
undetermined HPV types.
Eighty cervical intra-epithelial neoplasia (CIN) biopsy or
conization samples have also been selected: 40 high-grade
squamous intraepithelial lesions (HSIL) from the Institut
Curie Hospital (20 cases associated with HPV and 20 cases
not associated with HPV); 40 low-grade squamous
intraepithelial lesions (LSIL) from Dr. Isabelle Cartier
Pathology Laboratory (20 cases associated with HPV and
20 cases not associated with HPV). Median age was 28
years (range 18–62 years) for patients with LSIL and 36
years (range 19–59) for patients with HSIL.
All normal samples, invasive carcinomas and squamous
intraepithelial lesions were immediately frozen in liquid
nitrogen and stored at -80°C until used.
SSCP analysis and direct DNA sequencing
PCR-SSCP analysis was carried out on exons 7, 10, 15, 20
of the FGFR3 gene because these exons harbor all the acti-
vating mutations found previously in bladder and cervix
carcinomas and in most human skeletal disorders due to
FGFR3 mutations [5,21,22]. Samples that showed mobil-
ity shifts in SSCP analysis were further analysed by direct
bidirectional sequencing. SSCP and sequence analysis
were performed as previously described [16].
Semi-quantitative RT-PCR
Total RNA was extracted from each sample by caesium
chloride ultracentrifugation. Messenger RNA levels were
determined by multiplex semi-quantitative RT-PCR using
TBP (TATA binding protein) as internal control. Comple-
mentary DNA synthesis, PCR and analysis were per-
formed as described [23]. Twenty two cycles were
performed for the coamplification of FGFR3b and TBP.
Primer sequences for TBP (TFIID), and FGFR3b (XF2 and
TMR1) were as described [23,24].
Oligonucleotide microarray analysis
We used results from a global gene expression analysis of
30 primary invasive cervical carcinomas [15]. Histological
type was squamous cell carcinoma (SCC) for 20 samples
and adenocarcinoma (AC) for 10 samples. S249C FGFR3
mutation was associated with 3 of the analyzed SCCs.
Complementary RNA target was prepared and labeled as
described in the Affymetrix GeneChip Expression Analysis
Technical Manual, and hybridized to U133A Affymetrix
oligonucleotide array, representing 22,215 probe sets.
Gene expression data were normalized across all samples
and all probe sets, and log2-transformed. Significance
analysis of microarrays (SAM) [25] was used to perform
the two-class comparison for differentially expressed
genes between the 3 cervical SCCs with FGFR3 mutation
and the 17 cervical SCCs with wildtype FGFR3. The K-
nearest neighbor imputation was used to account for
missing data within the dataset. Output criteria selected
for SAM included at least threefold greater expression in
the FGFR3 mutated samples as compared to the FGFR3
wildtype samples. The false discovery rate (q value) was
arbitrarily set to 0.20.
Statistical Analysis
All results are given as mean ± standard error of the mean
unless otherwise specified. The Mann-Whitney U test was
used to compare continuous variables. For survival analy-
sis, patients who died because of the cervical cancer were
categorized as deaths. All other clinical evolution were
censored. Patients were subdivided into 2 or 3 groups of
equal size, according to the level of FGFR3b/TBP expres-
sion in cervical carcinoma. Survival analysis was carried
out using the Kaplan-Meier method. The difference
between survival curves was analyzed by the log-rank test.
Probability values of 0.05 or less were considered
significant.
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SAM analysis from gene expression data of 20 cervical carcinomas. genes 
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FGFR3 wildtype tumors (n = 17), identified by SAM analysis.
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